DOG Kongress 2015 Oraya Trailer mit Interview Dr. Ranjbar
Zusammenfassung des Symposiums auf der 113. DOG in Berlin mit Interview mit Dr. Mahdy Ranjbar zu den Studienergebnissen. Die Oraya-Therapie sichert den nachhaltigen Erfolg der Anti-VEGF-Therapie für Patienten mit neurovaskulärer AMD.
Oraya Therapy™ Stereotactic Radiotherapy for Wet AMD uses low-energy, highly targeted X-rays to treat wet AMD and is intended as a one-time procedure with the potential to maintain vision while reducing the required number of anti-VEGF injections. Full 2-year results from Oraya's INTREPID study were published in Ophthalmology, January 2015, and real world patient outcomes from three countries were present at EURETINA 15th Congress, September 2015. The Oraya Therapy is available in several treatment centres across Germany, Switzerland, and the United Kingdom.
http://www.orayainc.com/amd-clinical-outcomes/
